Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Use of a Bone Substitute Material in the Surgical Therapy of Furcation Defects

NCT06270303 · tracked via the Priya Life Science Sweden tracker
Phase
Not applicable
Started
2025-03-27
Last updated
2025-08-21

Condition(s) studied

PeriodontitisFurcation Defects

Investigational drug(s) / intervention(s)

Access flap & surgical debridementApplication of bone substitute material (BioOss Collagen)

Access flap & surgical debridement: Following surgical exposure, roots are carefully debrided.

Application of bone substitute material (BioOss Collagen): Following surgical debridement, the bone substitute material is applied to the furcation defect.

Study summary

The aim of this randomized clinical trial is to evaluate the potential benefit of the use of a bone substitute material in the treatment of furcation degree II-involved molars. The main question it aims to answer is: What is the benefit of the adjunctive use of a bone substitute material in the surgical treatment of furcation degree II-involved molars when compared to open-flap debridement alone?

200 patients with ≥1 molar presenting with a furcation defect degree II will be included and randomized to either control (open-flap debridement) or test treatment (open-flap debridement + bone substitute material). The primary outcome of the study is furcation closure defined as absence of clinically detectable furcation involvement degree \>I. Secondary outcomes include changes in bleeding on probing, probing depth, vertical and horizontal attachment levels, soft tissue level, marginal bone level, need for surgical retreatment, tooth loss, patient-reported outcomes and adverse events. A composite outcome based on furcation closure (degree ≤I) in combination with shallow probing depth (≤5 mm) and absence of bleeding on probing will also be evaluated.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Patients should present with at least one surgically accessible molar (in tooth position 6 or 7) diagnosed with a single furcation defect degree II (at any aspect). Following initial periodontal therapy, teeth to be included should present with one site with furcation defect degree II in combination with: * Bleeding on probing * Probing pocket depth of ≥6 mm * Soft tissue coverage of the furcation entrance Patients should present with a full mouth plaque score ≤25%. Exclusion Criteria: * Multiple deep furcation defects (degree II - III) at the same tooth * Vertical attachment loss \>50% at aspects not facing the furcation defect * Defects presenting with apico-marginal communication * Intake of systemic antibiotics within 6 months * Systemic conditions/medication impeding surgical intervention (e.g. uncontrolled diabetes, immunosuppressive medication)

Primary outcome measure(s)

  • Proportion of patients/teeth displaying furcation closure. — 6 months.
    Furcation closure defined as absence of clinically detectable furcation involvement degree \>I.
  • Proportion of patients/teeth displaying furcation closure. — 12 months.
    Furcation closure defined as absence of clinically detectable furcation involvement degree \>I.
  • Proportion of patients/teeth displaying furcation closure. — 3 years.
    Furcation closure defined as absence of clinically detectable furcation involvement degree \>I.
  • Proportion of patients/teeth displaying furcation closure. — 5 years.
    Furcation closure defined as absence of clinically detectable furcation involvement degree \>I.
  • Proportion of patients/teeth displaying furcation closure. — 7 years.
    Furcation closure defined as absence of clinically detectable furcation involvement degree \>I.
  • Proportion of patients/teeth displaying furcation closure. — 10 years.
    Furcation closure defined as absence of clinically detectable furcation involvement degree \>I.

Trial sites (1)

FacilityCityRegionStatus
Department of Periodontology, Institute of Odontology Gothenburg Sweden Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06270303 on ClinicalTrials.gov ↗ ← All trials in Sweden